Search

Zai Lab Ltd ADR

Atidarymo kaina

SektoriusSveikatos priežiūra

23.24 11.46

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

20.71

Max

24.04

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-607K

-51M

Pardavimai

-28M

100M

Pelnas, tenkantis vienai akcijai

-0.46

Pelno marža

-51.215

Darbuotojai

1,784

EBITDA

4.1M

-44M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+56.37% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-331M

2.1B

Ankstesnė atidarymo kaina

11.78

Ankstesnė uždarymo kaina

23.24

Naujienos nuotaikos

By Acuity

83%

17%

321 / 340 reitingas Healthcare

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-06 23:56; UTC

News

Clear Secure Inc launched a Corporate Memberships program to improve business travel, combining services like CLEAR+ and TSA PreCheck. Shares are trading higher after the announcement.

2026-08-06 23:56; UTC

News

Shares declined after-hours despite JP Morgan raising price target to $545.

2026-08-06 23:52; UTC

News

First Solar supports Section 232 action on polysilicon imports, benefiting U.S. manufacturing. Shares have moved sharply higher in after-market trading.

2026-08-06 23:51; UTC

News

The Invesco Currencyshares Japanese Yen Trust is lower in after-market hours, reflecting broader market movements amid ongoing U.S. and Japan currency interventions.

2026-08-06 23:51; UTC

News

LeMaitre Vascular Inc shares declined in after-market trading, nearing the lower end of their one-month range amid broader market volatility from Middle East supply concerns.

2026-08-06 23:51; UTC

News

Maravai LifeSciences reported second-quarter revenue of $51.4 million, exceeding expectations, but shares are lower in after-market trading amid a cautious full-year outlook.

2026-08-06 23:51; UTC

News

Fox Factory Holding Corp reported Q2 sales of $358.1 million, exceeding expectations. The company raised its full-year guidance, and shares advanced in after-market trading.

2026-08-06 23:51; UTC

News
Social Media

Twilio Inc reported second-quarter revenue of $1.50 billion, exceeding estimates. Shares are trading sharply higher in after-market hours following the strong results.

2026-08-06 23:51; UTC

News
Social Media

Indie Semiconductor reports second-quarter revenue of $64 million, exceeding estimates. Shares are trading higher in after-market hours on positive guidance for Q3.

2026-08-06 23:51; UTC

News
Social Media

Halozyme Therapeutics shares advanced in after-market trading following record second-quarter results, with revenue rising to $481 million and guidance increased for the year.

2026-08-06 23:51; UTC

News
Social Media

Onto Innovation shares rose in after-market trading following record revenue of $343 million and adjusted EPS of $1.93, both exceeding analyst expectations.

2026-08-06 23:51; UTC

News
Social Media

Airbnb Inc. reported second-quarter revenue of $3.61 billion, exceeding estimates. Shares rose significantly in after-market trading, despite earlier pulling back from a session high.

2026-08-06 23:46; UTC

News
Social Media

Republic Services reported strong second-quarter earnings and raised full-year adjusted EPS guidance. The stock was trading roughly flat in after-market hours.

2026-08-06 23:46; UTC

News

McDonald's shares are lower in after-market trading as CEO Chris Kempczinski discusses challenges with the company's value menu strategy and execution issues.

2026-08-06 23:42; UTC

Social Media
News

DraftKings shares are lower in after-market hours following a net loss of $67.6 million and revenue that fell short of estimates.

2026-08-06 23:41; UTC

News
Social Media

MP Materials reported second-quarter revenue of $108.5 million, exceeding expectations. Shares are trading higher in after-market hours following the earnings announcement.

2026-08-06 23:41; UTC

News
Social Media

Doximity reported fiscal Q1 revenue of $156.6 million, exceeding expectations. The company raised its FY2027 revenue guidance, driving shares higher in after-hours trading.

2026-08-06 23:41; UTC

News

nLIGHT Inc shares are sharply lower in after-market trading following mixed Q2 results and cautious guidance, projecting revenues below analyst expectations.

2026-08-06 23:41; UTC

Social Media
Event
News

Dropbox Inc. shares declined in after-market trading despite reporting Q2 revenue of $631.5 million, exceeding expectations. Concerns over stagnant growth contributed to the drop.

2026-08-06 23:36; UTC

News

First Business Financial Services Inc shares are higher in after-market hours, positioned near the upper end of their one-month trading range.

2026-08-06 23:36; UTC

News

Navient Corp reported second quarter earnings of $0.26 per share, exceeding expectations, but shares are trading lower in after-market hours amid revenue decline.

2026-08-06 23:36; UTC

News

Canaccord Genuity maintained its Hold rating on Zillow Group and lowered its price target to $40. Shares are trading roughly flat after market hours.

2026-08-06 23:32; UTC

News

Insulet Corp shares are lower in after-market hours following a downgrade to Market Perform by Leerink Partners and a reduced price target of $145.

2026-08-06 23:31; UTC

News

Arlo Technologies reported second-quarter revenue of $156 million and raised fiscal year 2026 guidance, contributing to a notable increase in after-market trading.

2026-08-06 23:31; UTC

News
Social Media

Akamai Technologies reported second-quarter revenue of $1.1 billion and adjusted EPS of $1.59, both exceeding analyst expectations. The stock is higher in after-market trading.

2026-08-06 23:31; UTC

News
Social Media

Figs Inc. reported second-quarter revenues of $196.6 million and raised its full-year growth forecast, contributing to a notable rise in after-market trading.

2026-08-06 23:31; UTC

News
Social Media

Ardelyx Inc. reports Q2 revenue of $118.1 million, missing expectations. Shares decline in after-market trading following revised financial guidance and a net loss of $16.7 million.

2026-08-06 23:31; UTC

News

Regenxbio Inc shares are higher in after-market hours following key milestones in its Q2 2026 earnings call, including FDA alignment for RGX-202's development.

2026-08-06 23:31; UTC

News
Social Media

Sweetgreen Inc. shares fell sharply in after-market trading following a significant net loss and revenue miss in its second-quarter results.

2026-08-06 23:31; UTC

News
Social Media

Trade Desk Inc shares declined sharply after reporting second-quarter revenue of $715 million, missing expectations, and providing weak guidance for the third quarter.

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

56.37% į viršų

12 mėnesių prognozė

Vidutinis 32.65 USD  56.37%

Aukščiausias 45 USD

Žemiausias 21.6 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

3

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

321 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat